AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
20.59
+0.26 (1.28%)
At close: Sep 2, 2025, 4:00 PM
20.61
+0.02 (0.10%)
After-hours: Sep 2, 2025, 4:39 PM EDT
AnaptysBio Employees
AnaptysBio had 136 employees as of December 31, 2024. The number of employees increased by 19 or 16.24% compared to the previous year.
Employees
136
Change (1Y)
19
Growth (1Y)
16.24%
Revenue / Employee
$905,618
Profits / Employee
-$974,956
Market Cap
577.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 136 | 19 | 16.24% |
| Dec 31, 2023 | 117 | 21 | 21.88% |
| Dec 31, 2022 | 96 | -6 | -5.88% |
| Dec 31, 2021 | 102 | 8 | 8.51% |
| Dec 31, 2020 | 94 | 5 | 5.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANAB News
- 6 days ago - Anaptys Announces Participation in September Investor Conferences - GlobeNewsWire
- 27 days ago - Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential - Seeking Alpha
- 3 months ago - AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement - Seeking Alpha
- 3 months ago - AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point - Benzinga
- 3 months ago - Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA - GlobeNewsWire
- 3 months ago - Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 - GlobeNewsWire
- 4 months ago - Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire